Optimizing Biologic Agents in Ulcerative Colitis and Crohn's Disease. - Wikidata - awgldk - TriplyDB

Optimizing Biologic Agents in Ulcerative Colitis and Crohn's Disease.

Optimizing Biologic Agents in Ulcerative Colitis and Crohn's Disease.

http://www.wikidata.org/entity/Q38549995

about

Pharmacokinetics in Wistar Rats of 5-[(4-Carboxybutanoyl)Amino]-2-Hydroxybenzoic Acid: A Novel Synthetic Derivative of 5-Aminosalicylic Acid (5-ASA) with Possible Anti-Inflammatory Activity Therapeutic drug monitoring of anti-tumour necrosis factor-α agents in inflammatory bowel disease.Host-Microbiota Interactions Shape Local and Systemic Inflammatory Diseases.RHB-104 triple antibiotics combination in culture is bactericidal and should be effective for treatment of Crohn's disease associated with Mycobacterium paratuberculosis.Clinical performance of an infliximab rapid quantification assay.Therapeutic drug monitoring of CT-P13: a comparison of four different immunoassays Optimization of biologic therapy in Crohn's disease.Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases.Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point-of-care quantitative test with two established ELISA assays.Proteomics and Lipidomics in Inflammatory Bowel Disease Research: From Mechanistic Insights to Biomarker Identification

P2860

Q36084796-C42BEA2C-B4D7-4D3D-829D-D1F57A12CA7D Q39030608-4C887837-3AA5-43BE-9C71-54EFAD1D670E Q39077398-6193B447-CB56-4A4B-9280-5367B5B8238E Q39679682-59B1482B-BAC4-4C2B-ABCD-96744DE63A5A Q41078459-30F6AF60-6496-4784-AA93-547CEAB19F07 Q41078498-2632D135-3640-43D6-A6FA-D46472F102D4 Q47389870-A279F753-371B-41DC-8143-9F3F9E390814 Q47805665-FD81F35B-F2B5-4EF7-B9B5-61AD29B0EC67 Q49126220-056D26B6-86C8-482D-B7BC-5D1E2EA2958C Q57156865-2A83CC44-E20C-4844-AB04-70E7D4325E8A

P2860

Optimizing Biologic Agents in Ulcerative Colitis and Crohn's Disease.

http://www.wikidata.org/entity/Q38549995

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Optimizing Biologic Agents in Ulcerative Colitis and Crohn's Disease.

@en

type

label

Optimizing Biologic Agents in Ulcerative Colitis and Crohn's Disease.

@en

prefLabel

Optimizing Biologic Agents in Ulcerative Colitis and Crohn's Disease.

@en

P1433

Q38549995-EDB3E1E7-C4B5-403B-B980-3770E7D1F6F7

P1476

Q38549995-BD537B06-ECFF-47A0-88BD-832568A07D55

P2093

Q38549995-4AD8FCAC-B286-45A5-8E2B-FEBD8211ACBA

Q38549995-8FD52AB7-E5A4-4893-950A-C45790D5FB67

P2860

Q38549995-023E6E0D-86C3-4043-BC02-5E14574D980E

Q38549995-029E86D7-3EB1-4B65-B2B4-23815455D268

Q38549995-06BDF7F7-4F77-4A54-A99A-37B6241244E6

Q38549995-0B8FCD05-2465-4135-AEEF-E08EE54D0E57

Q38549995-1289A2E2-F19E-4CDE-A6A2-9F20B7DE9DC4

Q38549995-160833CE-FA38-4AA2-8032-893C3EBDD6DF

Q38549995-16E6815C-4058-4749-B88A-7B4E30BAAB30

Q38549995-18D47E1C-1651-42C5-AC59-249F23C81344

Q38549995-19CE5F70-93C9-47E3-9320-F25DA5FD6AD9

Q38549995-1C13223D-252F-495B-99C8-C9B0C7AEA820

P2888

Q38549995-4D544830-EA92-41EB-B8B3-B3F894827FD3

P304

Q38549995-CD8DDE3B-F0BF-4983-A8ED-226A8DA368CB

P31

Q38549995-FD2E50E3-62F6-4F83-BAD8-C08AA9F6F19B

P356

Q38549995-5D0ABD00-3FF1-4AA7-A900-AF9AE28A05C5

P433

Q38549995-47929CC7-960C-45D2-A555-EC4E802EB278

P478

Q38549995-A2976F47-AC28-4D68-B59E-58FE61006971

P577

Q38549995-9572FAFF-A03D-4540-A67C-8A990653FB83

P6179

Q38549995-3CE250A8-07F6-4700-B90B-FCFC16CA9BF3

P698

Q38549995-FF392FFE-ED4E-4C8F-96A0-3E2F6069BC67

P356

S11894-015-0453-1

P1433

Current gastroenterology reports

P1476

Optimizing Biologic Agents in Ulcerative Colitis and Crohn's Disease.

@en

P2093

Alan C Moss

http://www.w3.org/2001/XMLSchema#string

Aoibhlinn O'Toole

http://www.w3.org/2001/XMLSchema#string

P2860

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

Optimizing the use of biological therapy in patients with inflammatory bowel disease

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease

Infliximab for induction and maintenance therapy for ulcerative colitis

Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data.

Meta-analysis: efficacy and safety of combination therapy of infliximab and immunosuppressives for Crohn's disease.

Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases.

Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders.

Vedolizumab as induction and maintenance therapy for Crohn's disease.

P2888

s11894-015-0453-1

P304

32

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11894-015-0453-1

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P577

2015-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1040440810

http://www.w3.org/2001/XMLSchema#string

P698

26188882

http://www.w3.org/2001/XMLSchema#string